Spotlight

Patients consistently felt possible TD impacted their lives, regardless of rating method, suggesting clinician assessments might miss its actual burden.

Researchers proposed a hypothesis linking dysfunctions in the striatum and the dorsal diencephalic connection system (DDCS) to classic tardive dyskinesia (TD).

Healthcare professionals should consider a complete therapeutic approach that includes the input of caregivers assisting patents with TD.

Resting-state functional MRI results show that patients with schizophrenia and tardive dyskinesia have altered cerebral regional homogeneity.

Physicians typically address movement disorders, such as tardive dyskinesia, during in-person examinations; however, a recent study shows that telehealth visits can be a part of treatment plans.

Patients with tardive dyskinesia being treated with vesicular monoamine transporter 2 inhibitors may see improvement in well-being along with TD symptoms.

Between 20% and 30% of patients with schizophrenia (SCZ)—and up to 50% patients with SCZ older than 50—develop tardive dyskinesia (TD), according to a study published in Genes & Genomics.

An uptick in biomarker testing for non-small cell lung cancer (NSCLC) over the past decade indicates an ongoing trend toward personalization of treatment choices.

First-line treatment that aligns with the results of biomarker testing and treatment guidelines is linked with better survival outcomes in patients with advanced or metastatic NSCLC.